Evogene Reports Significant Financial Adjustments for Fourth Quarter and Full Year 2025
On March 5, 2026, Evogene Ltd. (NASDAQ: EVGN) released its financial outcomes for the fourth quarter and full year of 2025. The company, recognized for its innovative work in computational chemistry, has strategically shifted its focus towards maximizing the potential of its proprietary platform, ChemPass AI™, which is central to creating small molecules tailored for pharmaceutical and agricultural applications.
During 2025, Evogene transitioned through extensive changes characterized by their strategic re-evaluation of technological assets and market orientation. Ofer Haviv, President and CEO of Evogene, underscored that the company redirected its efforts towards ChemPass AI™, enhancing its features to promote both novel molecule generation and optimization of multiple parameters right from the design phase. By concentrating on the pharmaceutical and agricultural spheres, Evogene aimed to foster sustainable, long-term value creation while divesting non-core assets and resizing its organization.
A pivotal element of this strategy involved collaborations with tech giants such as Google Cloud. For instance, an earlier partnership yielded a foundation model capable of precision design at an impressive 90% accuracy, based on extensive training over 38 billion molecular structures. Furthermore, a new collaboration initiated in early 2026 seeks to leverage AI to streamline workflows, minimize human errors, and potentially improve the quality and market readiness of candidate compounds.
Evogene’s portfolio focuses on proprietary small-molecule candidates renowned for three significant traits: their novel and diverse chemical structures, their multi-parameter optimization from the outset, and their high potency confirmed through precise experimental validation. The company adopts an integrated business model promoting partnerships alongside in-house advancements, fostering collaboration throughout the project lifecycle.
In the pharmaceutical sector, Evogene’s drug discovery programs, utilizing ChemPass AI™, saw multiple candidates advancing to testing phases through partnerships. Moreover, in agriculture, Evogene’s subsidiary, AgPlenus, is applying ChemPass AI™ for the development of innovative herbicides and fungicides, cemented by collaborations with established entities like Bayer and Corteva.
Financially, Evogene reported revenues for 2025 at approximately $3.9 million, down from $5.6 million in 2024, largely driven by alterations in AgPlenus’ revenue streams. The company experienced a significant reduction in operating expenses resulting in costs narrowing to around $13.8 million compared to $22.0 million in the preceding year. The effects of organizational realignment began to reflect in their fourth-quarter performance, showcasing a decrease in operating expenses to approximately $3.2 million.
As Evogene steps further into 2026, the firm remains steadfast in their mission to advance proprietary small-molecule product candidates, bolstered by the ChemPass AI™ platform. Their strategic re-focus, along with disciplined fiscal management, positions Evogene on a promising trajectory for sustainable value generation and robust partnerships in the pharmaceutical and agricultural realms. Evogene's underlying philosophy includes the essence of scientific innovation aligned with industry demands—a philosophy they term "Real-World Innovation." With these plans laid out, Evogene looks to the future with optimism while navigating the complexities of the biotechnology landscape.
In summary, Evogene has executed a thorough strategic pivot that not only responds to past challenges but also potentially sets a solid foundation for significant growth. As they advance with ChemPass AI™ at the core of their operations, stakeholders eagerly anticipate the development of innovative solutions in the pharmaceutical and agricultural sectors.
During 2025, Evogene transitioned through extensive changes characterized by their strategic re-evaluation of technological assets and market orientation. Ofer Haviv, President and CEO of Evogene, underscored that the company redirected its efforts towards ChemPass AI™, enhancing its features to promote both novel molecule generation and optimization of multiple parameters right from the design phase. By concentrating on the pharmaceutical and agricultural spheres, Evogene aimed to foster sustainable, long-term value creation while divesting non-core assets and resizing its organization.
A pivotal element of this strategy involved collaborations with tech giants such as Google Cloud. For instance, an earlier partnership yielded a foundation model capable of precision design at an impressive 90% accuracy, based on extensive training over 38 billion molecular structures. Furthermore, a new collaboration initiated in early 2026 seeks to leverage AI to streamline workflows, minimize human errors, and potentially improve the quality and market readiness of candidate compounds.
Evogene’s portfolio focuses on proprietary small-molecule candidates renowned for three significant traits: their novel and diverse chemical structures, their multi-parameter optimization from the outset, and their high potency confirmed through precise experimental validation. The company adopts an integrated business model promoting partnerships alongside in-house advancements, fostering collaboration throughout the project lifecycle.
In the pharmaceutical sector, Evogene’s drug discovery programs, utilizing ChemPass AI™, saw multiple candidates advancing to testing phases through partnerships. Moreover, in agriculture, Evogene’s subsidiary, AgPlenus, is applying ChemPass AI™ for the development of innovative herbicides and fungicides, cemented by collaborations with established entities like Bayer and Corteva.
Financially, Evogene reported revenues for 2025 at approximately $3.9 million, down from $5.6 million in 2024, largely driven by alterations in AgPlenus’ revenue streams. The company experienced a significant reduction in operating expenses resulting in costs narrowing to around $13.8 million compared to $22.0 million in the preceding year. The effects of organizational realignment began to reflect in their fourth-quarter performance, showcasing a decrease in operating expenses to approximately $3.2 million.
As Evogene steps further into 2026, the firm remains steadfast in their mission to advance proprietary small-molecule product candidates, bolstered by the ChemPass AI™ platform. Their strategic re-focus, along with disciplined fiscal management, positions Evogene on a promising trajectory for sustainable value generation and robust partnerships in the pharmaceutical and agricultural realms. Evogene's underlying philosophy includes the essence of scientific innovation aligned with industry demands—a philosophy they term "Real-World Innovation." With these plans laid out, Evogene looks to the future with optimism while navigating the complexities of the biotechnology landscape.
In summary, Evogene has executed a thorough strategic pivot that not only responds to past challenges but also potentially sets a solid foundation for significant growth. As they advance with ChemPass AI™ at the core of their operations, stakeholders eagerly anticipate the development of innovative solutions in the pharmaceutical and agricultural sectors.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.